 GNRH-leukotoxin chimeras |
| The practice of the present invention will employ, unless otherwise indicated, conventional ... |
|
| Polynucleotides encoding LKT 111 |
| The practice of the present invention will employ, unless otherwise indicated, conventional ... |
|
| Methods and compositions for the treatment of defects in lipoprotein metabolism |
| In one aspect, the invention provides a recombinant viral vector comprising the DNA of, or ... |
|
| Antisera against a PEB1 antigen from Campylobacter jejuni |
| It is an object of the present invention to provide highly specific and highly sensitive diagnostic ... |
|
| Gene encoding invasion protein of campylobacter species |
| OF PREFERRED EMBODIMENTS The following standard abbreviations for the amino acid residues are used ... |
|
| Preservatives for vaccines |
| New combinations of preservatives that pass antimicrobial testing requirements for United States P... |
|
| Methods and reagents for HLA class I A locus DNA typing |
| OF THE INVENTION To aid in understanding the invention, several terms are defined below. The terms ... |
|
| Immunomodulating compounds comprising d-isomers of amino acids |
| What is claimed is: 1. A peptide compound having immunomodulating activity comprising the sequence: ... |
|
| Targeted destruction of pests |
| The present invention is drawn to a safe, cost-effective, environmentally-friendly and ecologically-... |
|
| Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| OF THE INVENTION U.S. patents, U.S. patent application publications, U.S. patent applications, ... |
|
|
LktA deletion mutant of P. haemolytica
| Details |
Inventors: Briggs, Robert E.; Tatum, Fred M.;
Assignee: Biotechnology Research and Development Corporation (Peoria, IL)
Primary Examiner: Graser; Jennifer E.
Assistant Examiner:
Attorney, Agent or Firm: Banner & Witcoff, Ltd.
Mutants of P. haemolytica provide excellent safety and efficacy when used as vaccines in ruminants, for example cattle, sheep, and goats, subject to pneumonic pasteurellosis. They can be administered by a variety of routes. Especially preferred is the use in animal feeds. The mutants are not reverting and contain no foreign DNA and no introduced antibiotic resistance genes. |
|
DETAILED DESCRIPTION It is an object of the present invention to provide a P.
haemolytica bacterium useful as a vaccine strain.
It is another object of the present invention to provide a method of inducing immunity to pneumonic pasteurellosis in ruminants.
It is an object of the present invention to provide a vaccine strain against pneumonic pasteurellosis.
Another object of the invention is to provide a ruminant feed.
Another object of the invention is to provide a temperature sensitive plasmid for manipulation of P.
haemolytica.
These and other objects of the invention are achieved by one or more of the embodiments described below.
One embodiment of the invention provides a P.
haemolytica bacterium which expresses no biologically active leukotoxin, expresses a form of leukotoxin molecule which induces antibodies which specifically bind to leukotoxin, and contains no foreign DNA.
Another embodiment of the invention provides a method of inducing immunity to pneumonic pasteurellosis in ruminants.
A bacterium is administered to a ruminant.
Immunity to the bacterium is thereby induced.
The bacterium expresses no biologically active leukotoxin, expresses a form of leukotoxin molecule which induces antibodies which specifically bind to leukotoxin, and contains no foreign DNA.
Yet another embodiment of the invention provides a feed for ruminants.
The feed comprises a bacterium which expresses no biologically active leukotoxin, expresses a form of leukotoxin molecule which induces antibodies which specifically bind to leukotoxin, and contains no foreign DNA.
Even another embodiment of the invention provides a vaccine for reducing morbidity in ruminants.
The vaccine comprises a P.
haemolytica bacterium which expresses no biologically active leukotoxin, expresses a form of leukotoxin molecule which induces antibodies which specifically bind to leukotoxin, and contains no foreign DNA.
Still another embodiment of the invention provides a temperature sensitive plasmid.
The plasmid replicates at 30° C
|
| Related patents |
|
|
Malaria vaccine
OF THE INVENTION It has been established that a mixture of the following novel peptide compounds represents a preferred embodiment of the present invention, namely, Tyr-...
|
|
|
Protein copolymer malaria vaccine
OF THE INVENTION It has been established that a mixture of the following novel peptide compounds represents a preferred embodiment of the present invention, namely, F...
|
|
|
Vaccine against the sporozoite stage of malaria
OF THE INVENTION The P.vivax CS gene is set forth below (together with the amino acid sequence for which its codes) ##STR1## The DNA fragment chosen for insertion in ...
|
|
|
Malaria antigen
We claim: 1. A substantially pure polypeptide comprising the amino acid sequence of a glutamate-rich polypeptide (GLURP) derived from a Plasmodium falciparum antigen ("...
|
|
|
Oligopeptide lyophilisate, their preparation and use
OF PREFERRED EMBODIMENTS The following Examples illustrate the invention. EXAMPLE 1 Approx. 1.5 liters of water for injection purposes are prepared in a suitable glass ...
|
|
|
Antithrombin nucleotides and proteins from horn fly
Isolated proteins with antithrombin activity and nucleotide sequences encoding the proteins are provided. The protein named thrombostasin is isolated from the salivary ...
|
|
|
Immunogenic conjugates comprising leukotoxin peptide fragments
OF THE INVENTION Substances having molecular weights less than 1000 daltons are not ordinarily antigenic. However, antibodies can be raised to small molecules by ...
|
|
|
Interleukin-2-leukotoxin gene fusions and uses thereof
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, virology, recombinant DNA ...
|
|
|
Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, virology, recombinant DNA ...
|
|
|
GnRH-leukotoxin chimeras
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, virology, recombinant DNA ...
|
|
|
Drugs 
